Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail -- Update
July 30 2021 - 02:44PM
Dow Jones News
By Josh Beckerman
Regeneron Pharmaceuticals Inc.'s Covid-19 antibody cocktail
REGEN-COV has received an expanded Emergency Use Authorization from
the Food and Drug Administration.
The expanded authorization enables use for post-exposure
prophylaxis in certain people exposed to a SARS-CoV-2 infected
individual, or who are at high risk of exposure to an infected
person in institutional settings such as nursing homes or
prisons.
Regeneron said use of the cocktail in the U.S. "is rapidly
increasing to address ongoing outbreaks."
The seven-day average of new Covid-19 cases in the U.S.
approached 64,000 on July 29, up from 11,480 on June 19, while the
pace of vaccinations has slowed.
"With this authorization, the FDA specifically highlights the
needs of immunocompromised people, including those taking
immunosuppressive medicines," the company said.
Regeneron said that in those who require repeat dosing for
ongoing exposure, REGEN-COV can also now be administered
monthly.
Research results released last month showed that REGEN-COV
significantly reduced the risk of death for certain hospitalized
Covid-19 patients.
Regeneron shares were recently down 1% to $578.28. The company's
market capitalization is about $61.6 billion.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 30, 2021 14:39 ET (18:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2023 to Mar 2024